Clinical Trial Update: Effects of High-dose Intravenous Selenium (Selenase®) in Adult Patients Subjected to Elective All-cause Heart Surgery [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the effects of high-dose intravenous selenium (Selenase) in adults undergoing elective heart surgery has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Disease

Drugs mentioned

• Selenase (selenium)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Heart; Surgery, Heart, Functional Disturbance as Result, Self Efficacy | Phase 3 | Status: COMPLETED